ibandronic sodium monohydrate: clinical use

Prescribing considerations

• Confirm the licensed indication and appropriate oral, injection or infusion formulation.
• Correct hypocalcaemia and other mineral-metabolism disturbances before treatment; ensure adequate calcium and vitamin D intake.
• Assess renal function, particularly for intravenous treatment and concurrent nephrotoxic medicines.
• Assess oral health and osteonecrosis-of-the-jaw risk; arrange preventive dental assessment where appropriate.
• Ensure tablet recipients can follow fasting, swallowing and upright-position instructions.
• Periodically reassess benefit and risk, including atypical-fracture and jaw risks.

Contraindications and cautions

• Hypersensitivity to ibandronic acid or a formulation excipient
• Uncorrected hypocalcaemia
• For oral tablets: oesophageal abnormalities that delay emptying, such as stricture or achalasia
• For oral tablets: inability to sit or stand upright for at least one hour

Monitoring

• Serum calcium and relevant vitamin D or mineral abnormalities
• Renal function, especially with intravenous formulations or cancer treatment
• Oral and dental symptoms, invasive dental treatment and healing of mouth lesions
• New thigh, hip or groin pain
• Ocular inflammation symptoms
• Tablet administration technique, adherence and gastrointestinal tolerance

Clinical pharmacology

Ibandronic acid is a nitrogen-containing bisphosphonate with high affinity for bone mineral. It suppresses osteoclast activity without directly inhibiting bone formation. It is not metabolised, has little cytochrome P450 interaction potential, and is cleared through renal excretion and uptake into bone; oral bioavailability is low and highly food-sensitive.

Formulation and product differences

• The oral osteoporosis tablet requires strict fasting, plain-water and upright-position precautions and has additional oesophageal contraindications.
• The osteoporosis injection is a ready-to-use intravenous formulation administered by a healthcare professional.
• The oncology concentrate requires dilution and intravenous infusion in a specialist setting; it is licensed for breast-cancer bone metastases and tumour-induced hypercalcaemia.
• The concentrate must not be mixed with calcium-containing solutions; accidental intra-arterial or paravenous administration can cause tissue damage.

Solution for infusion

Route: Intravenous

Strengths: 1 mg, 2 mg, 6 mg

Tablet

Route: Oral

Strengths: 50 mg, 150 mg